← Back to Search

Beta-lactam Antibiotic

Continuous Antibiotic Dose Over 24 hours Arm for Pneumonia

Phase 4
Waitlist Available
Led By Charles Peloquin
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights

Study Summary

This trial will study the best way to give antibiotics to people with pneumonia caused by Gram-negative bacteria.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gram-negative Bacterial Resistance Emergence Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
Secondary outcome measures
Clinical Cure at Day 7 of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
Clinical Cure at the End of Therapy Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens
Hospital Length of Stay Between Patients Treated With Continuous and Intermittent Infusion Beta-lactam Regimens.
+6 more

Trial Design

2Treatment groups
Active Control
Group I: Continuous Antibiotic Dose Over 24 hours ArmActive Control1 Intervention
Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.
Group II: Intermittent Antibiotic Dose Over 30 minutesActive Control1 Intervention
Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,340 Previous Clinical Trials
715,661 Total Patients Enrolled
1 Trials studying Pneumonia
43 Patients Enrolled for Pneumonia
Food and Drug Administration (FDA)FED
171 Previous Clinical Trials
1,331,571 Total Patients Enrolled
1 Trials studying Pneumonia
7,530 Patients Enrolled for Pneumonia
Charles PeloquinPrincipal InvestigatorUniversity of Florida

Media Library

Cefepime (Beta-lactam Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT05102162 — Phase 4
Pneumonia Research Study Groups: Continuous Antibiotic Dose Over 24 hours Arm, Intermittent Antibiotic Dose Over 30 minutes
Pneumonia Clinical Trial 2023: Cefepime Highlights & Side Effects. Trial Name: NCT05102162 — Phase 4
Cefepime (Beta-lactam Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05102162 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the numerical representation of those taking part in this experiment?

"Indeed, the clinicaltrials.gov page indicates that this medical trial is actively seeking new participants. It was initially posted December 17th 2021 and edited most recently on February 24th 2022 with a goal of enrolling 240 individuals at one research site."

Answered by AI

Are there any vacancies available for individuals to participate in this research project?

"Per the clinicaltrials.gov page, this medical trial is presently recruiting suitable candidates. The listing was first posted on December 17th 2021 and was most recently amended on February 24th 2022."

Answered by AI

What type of medical condition is Continuous Antibiotic Dose Over 24 hours Arm typically prescribed for?

"Continuous Antibiotic Dose Over 24 hours Arm is commonly prescribed to treat intraabdominal infections, as well as communicable illnesses, lower respiratory tract infection (lrti), and pneumonia."

Answered by AI

Could I potentially partake in this experiment?

"Participants must be aged 18-100 and exhibit symptoms of pneumonia to join this trial. A total of 240 individuals will ultimately take part in the medical study."

Answered by AI

Does this clinical trial extend to adults aged eighteen or older?

"This medical trial is open to all patients aged between 18 and 100, however there are 31 separate trials designed specifically for minors while 166 studies have been tailored to those over the age of 65."

Answered by AI

To what extent does the Continuous Antibiotic Dose Over 24 hours Arm pose a risk to those who participate in it?

"Considering it is a Phase 4 trial and thus approved, the safety of Continuous Antibiotic Dose Over 24 hours Arm was rated 3 on our team's scale."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
2021. "BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05102162.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top